Medical Care Technologies Inc. develops and commercializes artificial intelligence applications across consumer software, imaging analysis, healthcare-oriented pre-screening and collectibles authentication. News about MDCE centers on its AI technology stack, including Snapshot Recipes, a mobile recipe application with AI-generated food and beverage content, and Real Game Used, a subsidiary developing a patent-pending AI authentication platform for sports memorabilia.
Company updates also cover AI imaging initiatives for dermatological analysis, wellness monitoring, product verification and automated quality control, as well as capital and asset-monetization activity through Infinite Auctions. Recurring announcements describe product redesigns, commercialization pathways, subsidiary activity, mobile-app user growth initiatives, and enterprise API or visual analytics use cases.
Medical Care Technologies (MDCE) outlined its software and subsidiary operations, including a first paid external enterprise agreement worth up to $250,000. Development is underway on an integrated inventory and sales system, and the company has expanded into AI model-training and software-integration consulting.
Full-year 2025 revenue was $1,071,812, with net income of $230,768. The company expects third-quarter 2026 results in the coming weeks to show its strongest quarterly revenue of the past year. Infinite Auctions and Real Game Used remain revenue contributors. Two health-imaging applications remain in internal testing and development without regulatory clearance. MDCE raised its Reg A offering price 100% to $0.00012 and plans further increases based on stock-price strength.
Medical Care Technologies (OTCID:MDCE) has begun development under its first paid external software agreement outside its subsidiaries, valued at up to $250,000.
The agreement, announced October 14, involves a client group that includes current and retired professional athletes. The first payment has been initiated, but is not described as received. Work covers an integrated web and enterprise software system, with consulting and administrative support during development, testing and deployment.
Separately, the company says a subsidiary is in the process of completing the largest agreement in the history of Medical Care Technologies and its subsidiaries. That agreement is not yet complete. Other work includes enterprise consulting for AI model training and internal evaluation of MDCE Melanoma Scan Beta and a wound-monitoring application.
Medical Care Technologies (MDCE) published updated internal technical evaluation results for Melanoma Scan Beta using an expanded human-submitted image dataset.
In controlled sequential captures, 86% of newly submitted photographs met the usability threshold, 89% of usable images were successfully placed on the body map, and 91% of paired sequential images achieved alignment for visual review. End-to-end completion without manual intervention was 84%. The company reported higher usability and registration results than in its first pass.
The results assess image handling, mapping and comparison, not clinical efficacy. The product remains in beta development without regulatory clearance, and volunteer image intake remains open.
Medical Care Technologies (OTCID:MDCE) highlighted revenue growth and its first external AI software agreement, valued at up to $250,000.
Fiscal 2025 revenue reached approximately $1.07 million, up 63% year over year, while net income increased 53% to $230,768. Management expects third-quarter 2026 revenue to exceed each of the preceding four quarters. The commercial relationship with Topps generated six-figure business activity in the initial month of the sales arrangement.
For the remainder of 2026 and into 2027, MDCE plans to prioritize revenue-producing opportunities, enterprise software commercialization and expanded subsidiary operations. Future financing and capital-structure decisions will depend on operational requirements, market conditions, available alternatives and applicable legal and contractual requirements.
Medical Care Technologies (MDCE) announced that subsidiary Real Game Used maintains a steady backlog of authentication work from customers and auction brands. The subsidiary recently launched an automated website submission system that lets customers initiate authentication requests online. Real Game Used remains an active revenue contributor within MDCE's broader operations.
Medical Care Technologies (MDCE) is working with task-based software technicians and external platforms to support technology and enterprise-services expansion. The work covers model refinement, integration, workflow development and platform scaling. Its first paid external software agreement is valued at up to $250,000. Subsidiaries Infinite Auctions and Real Game Used have also reached six figures in partnership activity within the arrangement's first few weeks.
Medical Care Technologies (MDCE) is expanding beyond AI software sales to provide businesses with AI model training and software integration consulting. Services include data preparation guidance, integration design and repeated model refinement.
The transition follows its first paid external software agreement, announced October 14, valued at up to $250,000 with a client group including current and retired NFL players. Subsidiaries Infinite Auctions and Real Game Used have also advanced a collectibles partnership that reached six figures in activity within its first few weeks.
Medical Care Technologies (MDCE) will post updated internal evaluation results for its Melanoma Scan Beta on its corporate website next week.
The update will cover a larger set of volunteer submissions, testing image intake and quality scoring, placement of images on a body map, and organization of successive images for visual review. First-pass testing showed that user photographs could move through those three stages. Volunteer intake remains open. The application remains in beta-stage development, has not received regulatory clearance, and is not a substitute for professional medical screening or evaluation.
Medical Care Technologies (MDCE) expects third-quarter 2026 revenue to exceed every trailing quarter over the last twelve months. The anticipated performance reflects initial revenue from its first paid external software agreement and sales through its subsidiaries' collectibles partnership. Full results are due in the coming weeks.
Full-year 2025 revenue rose 63% to $1,071,812 from $656,402 in 2024, while net income increased 53% to $230,768. Management anticipates further revenue growth in coming quarters and throughout 2027, without projecting specific results. Share issuance over the past year diluted holders; management is evaluating capital-structure steps intended to limit future dilution, but has announced no specific action.
Medical Care Technologies (MDCE) outlined commercialization plans following its first external enterprise software agreement, valued at up to $250,000.
The agreement was announced October 14, execution is underway, and the first payment has been initiated. The company is evaluating additional software opportunities. StrainScan Pro enterprise demonstrations continue as it works toward first enterprise clients. Subsidiaries Infinite Auctions and Real Game Used completed an initial six-figure game-worn memorabilia sale to Topps; additional supply discussions remain open. Melanoma Scan Beta and Wound Monitoring remain in development without regulatory clearance. The company expects another round of internal Melanoma Scan Beta evaluation results in the near term.